4DMedical Limited (4DX.AX)
| Previous close | 0.6050 |
| Open | 0.6100 |
| Bid | 0.6100 x 0 |
| Ask | 0.6250 x 0 |
| Day's range | 0.6000 - 0.6300 |
| 52-week range | 0.4500 - 1.2700 |
| Volume | |
| Avg. volume | 734,424 |
| Market cap | 238.745M |
| Beta (5Y monthly) | 1.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings date | 27 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.13 |
PR NewswireImbio to be Acquired by 4DMedical Creating Comprehensive Cardiothoracic Image Analysis Portfolio
Imbio, Inc. (a portfolio company of Minneapolis-based Invenshure LLC), a provider of medical imaging analysis technologies for chronic lung and cardiothoracic diseases, announces it has entered a binding agreement to be acquired by 4DMedical, a leading producer of advanced lung function imaging software. The combined technology offering will turn any standard chest CT into a much broader Cardiothoracic Analysis, immediately providing functional, structural, and risk-based analysis for both lung
PR Newswire4DMedical and Imbio Merge to Create Comprehensive Cardiothoracic Image Analysis Portfolio
4DMedical announces it has entered a binding agreement to acquire Imbio (a portfolio company of Minneapolis-based Invenshure). As the creators of groundbreaking lung imaging technologies, 4DMedical aims to revolutionize respiratory imaging and ventilation— for improved lung disease detection and management. Imbio technology complements those products perfectly, delivering quantitative and personalized imaging analysis for patients suffering from both acute and chronic diseases.
- PR Newswire
4DMedical receives U.S. FDA clearance for CT LVAS Lung Function Scanning Software
4DMedical, the leading producer of advanced lung function imaging software has received FDA clearance for its CT-based ventilation product (CT LVAS™). CT LVAS, designed for use with computed tomography scans, joins 4D Medical's XV LVAS® imaging software cleared for use with fluoroscopy In the United States. The FDA clearance for CT LVAS dovetails with the upcoming 4DMedical product, CT:VQ™. CT:VQ will enable quantitative perfusion (blood flow) data and visualizations to be extracted from CT scan
